Merck gets FDA priority review for Recarbrio in HABP/VABP
Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA)…
Read More...
Read More...
